Previous studies have shown that intracellular calcium ion dysfunction may be an etiological factor in affective illness. Nimodipine (NMD) is a Ca 2 þ channel blocker that has been extensively investigated for therapy of central nervous system (CNS) disorders. In this work, we have evaluated the antidepressantlike activity of nimodipine encapsulated into liposomes (NMD-Lipo) in mice through tail suspension and forced swim assays, as well as MAO B activity. During the tail suspension test, the administration of NMDLipo at 0.1, 1 and 10 mg/kg was able to promote a reduction in the immobility time of animals greater than the positive control (imipramine). In the forced swim test, the immobility time of mice treated with NMD-Lipo was reduced. This reduction was significantly greater than that found in the animals treated with imipramine and paroxetine. This may suggest that NMD-Lipo provides more antidepressant-like activity than in positive controls. The groups that received a combination of liposomal NMD and antidepressant drugs showed lower immobility time than the groups, which were treated only with imipramine or paroxetine. The mice treated with the combination of NMD-Lipo and reserpine presented an increase in the time of immobility compared with animals treated only with NMD-Lipo. There was a significant decrease in MAO B activity in animals treated with NMD-Lipo compared with untreated animals. The results of the tail suspension test, forced swim test and MAOB activity suggested that the antidepressant activity of NMD-Lipo may be related to an increase in the cerebral monoamine concentrations.
Introduction
Depression is a highly prevalent and recurrent mental disorder that impacts all aspects of human life (Socała et al., 2012) . Research has shown that depression probably originated during the evolutionary process. Some studies have supported this thesis by arguing that being in a state of depression makes people focus on solving problems. Also, traces of depression may indicate that the affected person needs some help, besides discouraging individuals from risky behavior (Wittman, 2014) . On the other hand, when depression progresses from a mild state to a severe condition, the disease becomes alarming. This pathology is one of the major causes of disability in the world, representing a heavy social burden, and is considered a lifetime risk .
Treatment-resistant depression is a frequent condition in patients. Statistics show that 50-60% of people treated with antidepressant drugs obtain clinically insignificant results (Fornaro et al., 2014) . Therefore, strategies used to improve the treatment of this disease include the addition of one or more non-antidepressant drugs to an existing therapy or the use of agents to target specific symptoms of depression. Combined therapy involving the use of two or more antidepressant drugs has been increasingly implemented (Papakostas, 2009) .
The pathogenesis of neuropsychiatric diseases and the mechanisms of action of drugs used in their treatments are still not well established. However, it is well known that alterations commonly occur in many diseases of the central nervous system (CNS). For example, rises in intracellular calcium concentration cause an increased contraction of the brain vasculature, which reduces blood flow in the organ (Xu et al., 2013) . In addition, excessive penetration of calcium in neurons causes a process known as excitotoxicity that induces neuronal damage and cell death by necrosis or apoptosis (Justin et al., 2014 and Aslan et al., 2009 ).
Research has shown that the excessive flow of calcium through the membrane, which results in increased intracellular levels of this cation, may play a role in the pathophysiology of affective CNS disorders (Maigaard et al., 2012 ), epileptiform activity (N'Gouemo, 2013 and the induction of anxiety (Kumar et al., 2013) .
In this way, an increase in calcium concentrations in platelets and lymphocytes of depressed and bipolar patients suggests that increased intracellular concentrations of this cation may play a role in the pathophysiology of depression and bipolar disorder (Dubovsky et al., 2014; Dubovsky et al., 1994; Dubovsky et al., 1992 and Dubovsky et al., 1989) . This finding was reinforced by the discovery that some drugs used for treating depression and bipolar disorder, such as tricycle antidepressants and lithium, cause a blockage in the calcium channels, indicating that this mechanism may contribute to their therapeutic effect (Roedding et al., 2006 and Grunze et al., 1996) . Based on this data, calcium channel blockers may be considered a possible therapeutic agent for an effective treatment of affective illnesses of CNS.
Nimodipine (NMD) is a central Ca 2 þ channel blocker and has a high permeability through the blood brain barrier (BBB). Because of this, NMD has been extensively investigated in the therapy of CNS disorders (Sygnecka et al., 2015) . It has been shown to have antidepressant properties in rats (Katagiri et al., 2001 ) and humans (Frye et al., 2003 , Yingling et al., 2002 and Pazzaglia et al. 1995 . However, the clinical use of NMD is limited by its low solubility in gastrointestinal fluids and high first-pass effect in the liver, which leads to a low bioavailability after oral administration (Bege et al., 2013 and Sun et al., 2013) . Nanotechnology offers an interesting approach for improving the therapeutic management of CNS diseases. In general, liposomal drug-loaded formulations are superior to free drugs in their pharmacokinetic and therapeutic effects (Wong et al., 2012) . Our recent studies have demonstrated that NMD encapsulated into liposomes presents anxiolytic (Moreno et al., 2014) and anticonvulsant activities in mice (Moreno et al., 2015) . For these reasons, liposomes seem to be a suitable vehicle for the administration of NMD.
An animal model that perfectly mimics the symptoms of depression in human patients is hardly ever achieved. Animals not only lack consciousness of self, self-reflection and consideration of others, but also symptoms of depression such as suicidal tendencies and depressed mood are difficult to detect in non-human beings (Deussing, 2006) . However, there are a number of symptoms of this disease that can be reproduced in animals such as anxiety, anhedonia, sleep disturbances, hormonal dysregulation, etc., which can be used for drug tests with the view to acquiring understanding of neurological diseases (Schmidt, 2011) .
The tail suspension and the forced swim tests are widely used for evaluating antidepressant activity of compounds in preclinical trials (Rollema et al., 2009) . The mechanism of the effects evaluated using these tests has yet to be well established, but it is believed that they may reflect conformational changes occurring in the neurotransmitter receptors and the signal transduction receptor mediated systems (Kim et al., 2010) .
Monoamine oxidases (MAO) are a class of mitochondrial enzymes involved in the degradation of biogenic amines. Monoamine oxidase inhibitors (MAOIs) have been used in clinical therapy owing to their antidepressant effects. However, the use of MAOIs for the treatment of depression has diminished since the discovery that MAOIs ingested with tyramine can result in cardiovascular reaction ("cheese effect") (Ghazaleh et al., 2015) . On the other hand, the finding that the selective inhibition of monoamine oxidase B (MAO B ) does not cause "cheese effect" suggests that drugs causing MAO B inhibition are suitable for the therapy of affective disorders (Finberg, 2014) .
Based on the abovementioned, we evaluated the antidepressant-like activity of nimodipine-loaded liposomes (NMD-Lipo) in treated mice using the tail suspension and forced swim tests. Furthermore, we examined MAO B activity in the hippocampus of treated mice after the forced swim test.
Results

Drug content and encapsulation rate of NMD-Lipo
NMD-Lipo presented a drug content of 0.967 0.74 mg/mL and encapsulation efficiency of 997 0.67%. These results are in agreement with our previous studies (Moreno et al., 2014 (Moreno et al., , , 2015 .
Tail suspension test
The results are summarized in Table 1 . In the tail suspension test, the animals treated with a dose of 50 mg/kg of imipramine showed a significant decrease in immobility time (66.6%) when compared with the saline-treated group. The mice treated with NMD-Lipo at the doses of 0.1, 1 and 10 mg/kg also showed a reduction in immobility time (78.0%, 82.4% and 88.0%, respectively) in comparison with the saline-treated group.
Forced swim test
The results are summarized in Table 2 . In the forced swim test, there was a decrease in the immobility time of imipramine and paroxetine-treated mice (63.3% and 56.3%, respectively). In addition, an increase in total immobility duration in mice treated with reserpine (27.7%) when compared with saline-treated group was found. The animals receiving NMD-Lipo at doses of 0.1, 1 and 10 mg/kg showed a significant reduction in immobility time (88.6%, 95.2% and 97.4%, respectively) compared with the salinetreated group.
The mice treated with NMD-Lipo at a dose of 10 mg/kg plus imipramine, paroxetine and reserpine, showed an increase in swimming time (90.3%, 69.0% and 48.1%, respectively) when compared to the saline-treated group.
Measurement of MAO B activity
The results are summarized in Fig. 1 . In the measurements of MAO B activity, there were no significant differences in animals treated with imipramine, paroxetine and reserpine, when compared with the saline-treated group. There was a significant decrease in MAO B activity of animals treated with NMD-Lipo at doses of 0.1, 1 and 10 mg/kg (41.2%, 55.9% and 73.5% respectively) compared with the animals treated with saline (p o 0.05). In addition, a significant decrease in enzymatic activity of mice treated with NMD-Lipo was observed at a dose of 10 mg/kg with the subsequent addition of imipramine, paroxetine and reserpine (44.1%, 56.2% and 61.8% respectively) when compared with the saline-treated group (p o0.05).
Discussion
In the tail suspension test, the administration of NMD encapsulated into liposomes at doses of 0.1, 1 and 10 mg/kg was able to promote a greater reduction in immobility time of animals (34.3%, 47.5% and 64.2%) than imipramine treatment. This result suggests that NMD-Lipo presents a significant dose-dependent antidepressant-like activity in mice, even better than that of the drug chosen as a positive control.
In the forced swim test, the immobility time of mice treated with NMD-Lipo at doses of 0.1, 1 and 10 mg/kg was reduced. Again, the effect was dose-dependent. This reduction was significantly greater than that found in the animals treated with imipramine (34.3%, 47.9% and 64.16% higher, respectively) and paroxetine (63.0%, 70.4% and 79.8% greater, respectively). These findings reinforced the hypothesis that states that liposomal NMD provides a better antidepressant-like activity in mice than that of the positive control.
Furthermore, the animal groups treated with the combination of NMD-Lipo and antidepressant drugs showed a lower immobility time and greater antidepressant-like effect than groups treated only with imipramine or paroxetine. The satisfactory results in the administration of both NMD-Lipo and antidepressant drugs suggest an indication of combined therapy to treat depression.
Mice treated with the combination of NMD-Lipo at a dose of 10 mg/kg and reserpine showed an increase of 78.1% in immobility time compared with the animals treated only with NMD-Lipo. This finding can be explained by the fact that the administration of reserpine in rodents depletes brain monoamine oxidases (Souza et al., 2013) , which is the opposite effect of drugs used in the treatment of depression. These data may suggest a possible mechanism of action for the antidepressant activity of NMD-Lipo related to an increase in the concentration of brain monoamine oxidases.
In the measurement of MAO B activity, it was observed that treatment with saline, imipramine, paroxetine, and reserpine did not cause the inhibition of MAO B . On the other hand, treatment with NMD-Lipo at all doses tested (0.1, 1 and 10 mg/kg) resulted in a significant decrease in enzyme activity. This may suggest that NMD-Lipo causes a dose-dependent MAO B inhibition, which might be responsible for the NMD antidepressant effect. Animals treated with combinations of NMD-Lipo and paroxetine, imipramine and reserpine showed lower MAO B activity than untreated animals. However, those animals presented higher enzymatic activity than those treated only with the liposomal NMD at a dose of 10 mg/kg. This is due to the fact that paroxetine, imipramine and reserpine do not cause enzyme inhibition.
Depression has been recognized and treated by different therapeutic approaches over centuries (Rodrigues et al., 2014) . In the present study, imipramine was chosen as a positive control because it is the oldest tricycle antidepressant, and is commonly used in the treatment of endogenous depression and illness-associated depression (Obuchowicz et al., 2012) . The pharmacological action of this drug produces an increase in the concentration of monoamines through presynaptic monoamine reuptake inhibition (Yasuda et al., 2014) .
Paroxetine has also been used as a positive control because it is a selective serotonin reuptake inhibitor widely used in therapy of depression (Murata et al., 2013) . Reserpine is an alkaloid isolated from Rauwolfia serpentina, which was chosen as a negative control since it depletes monoamines by irreversibly blocking vesicular monoamine transporter. In mice, reserpine causes various symptoms presented in depression, such as hypoactivity, lethargy and anhedonia (Kyzar et al., 2013) . The doses of imipramine, paroxetine and reserpine were chosen according to the literature (Campêlo et al., 2011 and Oliveira et al., 2013) .
As reported, excessive calcium influx through the membrane and increased intracellular calcium concentrations play a role in the physiopathology of neuropsychiatric diseases (Dubovsky et al., 2014) . In this scenario, nimodipine administered at a dose of 5 mg/ kg showed antidepressant properties in rats, as previously reported (Katagiri et al., 2001) . Even though this calcium channel antagonist has also proved to be useful in the treatment of affective illness in humans, it has never been administered as a single component of depression therapy; instead, it is always used in combination with other antidepressants (Frye et al., 2003 , Grunze et al., 1996 and Pazzaglia et al., 1995 . This is probably due to NMD high first-pass metabolism in the liver, which results in low bioavailability (Salgado-Figueroa et al., 2015) .
Previous research has shown that NMD encapsulated in liposomes presents effects on the CNS significantly greater than the free drug in several tests, suggesting that the liposomes promoted a controlled drug release by increasing its bioavailability and consequently its effect (Moreno et al., 2014 (Moreno et al., , 2015 . Hence, this liposomal formulation was chosen for the tests of antidepressant activity of the drug.
We have used the tail suspension test for determining a possible antidepressant-like activity of NMD-Lipo in treated mice. The forced swim test was carried out to confirm the NMD-Lipo antidepressant-like activity suggested in the tail suspension test. The doses were chosen based on previous studies with free nimodipine (Frye et al., 2003 , Grunze et al. 1996 , Katagiri et al. 2001 and Pazzaglia et al. 1995 and liposomal NMD (Moreno et al., 2014 (Moreno et al., , , 2015 .
The significant reduction in immobility time in mice treated with NMD-Lipo in the tail suspension and forced swim tests, as well as the increased immobility of rodents treated with reserpine and NMD-Lipo, are evidence that the liposomal NMD displays drug antidepressant-like activity by increasing the concentration of brain monoamines. The decrease in MAOB activity in animals treated with the liposomal formulation containing NMD strengthens this hypothesis. More studies are needed to unravel the antidepressant activity of NMD-Lipo; however, NMD-loaded liposomes appear to be a promising approach for depression therapy.
Experimental procedure
Animals
Eight-week-old male Swiss mice (weighing 25-30 g) were obtained from Central Animal House of the Federal University of Piauí (Teresina, Brazil). Animals were housed in polypropylene cages with wire covers at 257 2°C under 12:12-h light-dark cycle (light on from 07:00 h to 19:00 h). They were supplied with commercial food pellets (Nutrilabor, Campinas, Brazil) and water ad libitum, and were acclimatized to laboratory conditions for 7 days before being subjected to experimental assays. The experimental protocol and procedures was approved by the Ethics Committee on Animal Experimentation of the Federal University of Piauí (CEEA/UFPI N°014/11). All experiments were performed according to the Guide of care and use of laboratory animals from the US Department of Health and Human Services (Washington, 1985) .
Drugs and chemicals
Cholesterol (Chol), trehalose, nimodipine, imipramine hydrochloride, paroxetine hydrochloride, reserpine and benzylamine were obtained from Sigma-Aldrich (St. Louis, USA). Soybean phosphatidylcholine (PC) (Lipoid S 100 s ) was purchased from Lipoid GmbH (Ludwigshafen, Germany). Solvents and other chemicals supplied by from Merck (Darmstadt, Germany). All drugs were administered intraperitoneally. To study the association of the formulation with antidepressant drugs and reserpine, the drugs used as control (imipramine, paroxetine and reserpine) were administrated 30 min before NMD-Lipo.
Preparation and characterization of liposomes containing nimodipine (NMD-Lipo)
Liposomes containing nimodipine (NMD-Lipo) were prepared and characterized as previously reported (Moreno et al., 2014) . The liposomal formulation was produced using the method of hydrating thin lipid film. The content of nimodipine in liposomes was determined using UV spectroscopy at 237 nm. The encapsulation efficiency of nimodipine into liposomes was determined by the technique of ultrafiltration/ultracentrifugation using Ultrafree s units (Millipore, USA). A liposomal sample aliquot (400 mL) was transferred to filtering units and subjected to ultracentrifugation at 8776 g for 1 h. The amount of encapsulated nimodipine was obtained from the difference between the total quantity measured in the formulation and the filtrate obtained after centrifugation.
Tail suspension test
The mice were divided into five groups of eight animals each and treated intraperitoneally as follows: 0.9% saline (negative control), imipramine at a dose of 50 mg/kg (positive control) and NMD-Lipo at doses of 0.1, 1 and 10 mg/kg (groups NMD-Lipo 0.1, 1 and 10 respectively). The animals were then subjected to the tail suspension test after 30 min of drug administration.
The total duration of immobility induced by tail suspension was measured according to a previously reported method (Steru et al., 1985) . Mice were suspended 58 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. The time during which mice remained immobile was quantified during a test period of 6 min. Mice were considered immobile only when they hung passively and completely motionless. Immobility was regarded as depression-like behavior (behavioral despair).
Forced swim test
The mice were divided into ten groups of eight animals each and treated intraperitoneally as follows: 0.9% saline (negative control), imipramine at a dose of 50 mg/kg, paroxetine at a dose of 20 mg/kg, reserpine at a dose of 0.25 mg/kg (positive controls) and NMD-Lipo at doses of 0.1, 1 and 10 mg/kg (groups NMD-Lipo 0.1, 1 and 10, respectively). To study the effect of the formulation tested in combination with antidepressant drugs and reserpine, mice received NMD-Lipo at a dose of 10 mg/kg in combination with imipramine at a dose of 50 mg/kg (group NMD-Lipo 10 plus Imipramine), NMD-Lipo at a dose of 10 mg/kg in combination with paroxetine at a dose of 20 mg/kg (group NMD-Lipo 10 plus Paroxetine) and NMD-Lipo at a dose of 10 mg/kg in combination with reserpine at a dose of 0.25 mg/kg (group NMD-Lipo 10 plus Reserpine). Mice were subjected to the forced swim test 30 min after drug administration.
The test procedure was carried out according to the method describe by Porsolt et al. (1977) . In brief, mice were individually forced to swim in glass beakers (height 25 cm, diameter 10 cm) containing 15 cm of water maintained at a temperature of 25°C. The time that the mice remained immobile was quantified during a test period of 5 min. The total immobility time was defined as the total amount of time during which the mice remained immobile or made only small limb movements necessary for floating. Immobility was regarded as depression-like behavior (behavioral despair).
Preparation of brain and liver mitochondria for MAO B assay
After the forced swim test, the mice were sacrificed by cervical dislocation and their brains and livers were removed and dissected. Mitochondria were isolated from liver and brain of animals according to the method described by Gazzotti et al. (1979) . The organs were weighed and placed in a homogenization medium (pH: 7.4, temperature: 4°C). Subsequently, the organs were sliced and grounded to obtain a uniform homogenate. Homogenates were centrifuged at 1100 g for 15 min at 4°C and the supernatants were collected and centrifuged again at 1100 g rpm for 25 min at 4°C. The pellets obtained were resuspended in 25 mL of homogenization medium and then centrifuged at 1100 g rpm for 25 min.
The mitochondrial pellets were resuspended in a homogenization medium to a final volume of 4 mL. The samples of isolated mitochondria were used to determine the protein concentration by applying the method described by Lowry et al. (1951) .
Measurement of MAO B activity
MAO B activity was measured using benzylamine as substrate, according to the method of Tabor et al. (1954) . A sample of 620 mg of mitochondrial proteins (90 mL) was dissolved in 2 mL of 0.1 M sodium phosphate buffer (pH 7.4). The reaction was started by the addition of 1 mM benzylamine and the progress of the reaction (benzaldehyde formation) was measured in a spectrophotometer UV/visible at 250 nm. The maximum rate of MAO B activity was expressed as micromoles per milligram of protein per minute. The activity of the MAO B enzyme was assessed for 6 h after isolation of mitochondria.
Statistical analyses
Data values are expressed as mean 7standard error of mean (SEM) of the number of animals used in the experiments. Differences between groups were determined by analysis of variance (ANOVA) followed, when a difference was detected, by the Student-Newman-Keuls t-test with post hoc test. The significance level for rejecting the null hypothesis was always p r0.05.
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